Payment overview · 2025
General Payments
$978.12
65 reported records · 12 companies
Healthcare provider profile · identity verified
Thomas Murray Baker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAINT MARYS, PA · NPI 1093756207
Verified facts
What the public records show
CMS Open Payments records show Thomas Murray Baker, M.D. received $978.12 in general payments during 2025 across 65 reported records.
Novo Nordisk Inc accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $247.87 | 25.3% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $209.45 | 21.4% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.08 | 14.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.96 | 14.6% | 9 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.87 | 6.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.29 | 4.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.32 | 4.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.57 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.84 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.65 | 1.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.61 | 1.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $6.61 | 0.7% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $978.12 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $169.19 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $142.96 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $129.02 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $110.75 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.35 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $80.43 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $79.14 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.68 | 4 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $67.87 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.94 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.57 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.09 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $6.61 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 109 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
109 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 226 |
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 518 | 133 |
| Gabapentin | Gabapentin | 481 | 98 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 469 | 105 |
| Lisinopril | Lisinopril | 421 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 387 | 118 |
| Losartan Potassium | Losartan Potassium | 313 | 99 |
| Potassium Chloride | Potassium Chloride | 303 | 78 |
| Metformin Hcl | Metformin Hcl | 287 | 85 |
| Alprazolam | Alprazolam | 281 | 69 |
| Montelukast Sodium | Montelukast Sodium | 281 | 79 |
| Furosemide | Furosemide | 271 | 81 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 249 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 238 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 63 |
| Meloxicam | Meloxicam | 233 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 74 |
| Simvastatin | Simvastatin | 223 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 55 |
| Omeprazole | Omeprazole | 184 | 63 |
| Eliquis | Apixaban | 176 | 42 |
| Lorazepam | Lorazepam | 165 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 30 |
| Famotidine | Famotidine | 144 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 136 | 32 |
| Spironolactone | Spironolactone | 136 | 32 |
| Allopurinol | Allopurinol | 135 | 37 |
| Carvedilol | Carvedilol | 134 | 45 |
| Sertraline Hcl | Sertraline Hcl | 133 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 39 |
| Trazodone Hcl | Trazodone Hcl | 122 | 28 |
| Atenolol | Atenolol | 121 | 36 |
| Baclofen | Baclofen | 121 | 28 |
| Jardiance | Empagliflozin | 113 | 26 |
| Farxiga | Dapagliflozin Propanediol | 109 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 32 |
| Metformin Hcl Er | Metformin Hcl | 104 | 29 |
| Tramadol Hcl | Tramadol Hcl | 97 | 35 |
| Hydromorphone Hcl | Hydromorphone Hcl | 95 | suppressed |
| Pregabalin | Pregabalin | 93 | 21 |
| Ozempic | Semaglutide | 92 | 20 |
| Prednisone | Prednisone | 92 | 39 |
| Xarelto | Rivaroxaban | 92 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 20 |
| Lamotrigine | Lamotrigine | 83 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 27 |
| Aripiprazole | Aripiprazole | 78 | 15 |
| Warfarin Sodium | Warfarin Sodium | 78 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 25 |
| Cefdinir | Cefdinir | 72 | 61 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 17 |
| Fentanyl | Fentanyl | 62 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 58 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 13 |
| Sucralfate | Sucralfate | 56 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 13 |
| Entresto | Sacubitril/Valsartan | 54 | 12 |
| Ezetimibe | Ezetimibe | 54 | 15 |
| Mirtazapine | Mirtazapine | 53 | 12 |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Ramipril | Ramipril | 50 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 11 |
| Bumetanide | Bumetanide | 47 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Fluconazole | Fluconazole | 46 | 27 |
| Irbesartan | Irbesartan | 46 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Chlorthalidone | Chlorthalidone | 44 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Glipizide Er | Glipizide | 43 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 18 |
| Lovastatin | Lovastatin | 42 | 13 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Finasteride | Finasteride | 41 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 23 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 15 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Buspirone Hcl | Buspirone Hcl | 35 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Oxycontin | Oxycodone Hcl | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 21 |
| Celecoxib | Celecoxib | 31 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | 11 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Topiramate | Topiramate | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Nystatin | Nystatin | 28 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 12 |
| Acyclovir | Acyclovir | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Azithromycin | Azithromycin | 24 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | 11 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 16 |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Metronidazole | Metronidazole | 19 | 11 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $978.12 · 65 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, JARDIANCE, KEVEYIS, LEQVIO, LifeVest, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, UBRELVY, Wegovy, YUPELRI, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error